Big player in embryonic stem cell research bails out.

One of the biggest companies currently involved in embryonic stem cell research is getting out.

This was a major surprise and may impact the future of embryonic stem cell research.

A story posted on LifesitesNews notes:

Out of nowhere the Geron Corporation announced last week it was not only halting the first clinical trial of embryonic stem cell treatment on humans but getting out of the embryonic stem cell business altogether.

To understand how big a blow to the embryonic stem cell industry this was, you first must know it was Geron that funded the University of Wisconsin Madison’s original research back in 1995, which resulted in the first cultures of embryonic stem cells. It was Geron that started this whole mess.

Geron went on to comprise one-third of the triune that controlled which company or university got access to embryonic stem cell lines, along with the Wisconsin Alumni Research Foundation and the National Institutes of Health.

In its position of power Geron grabbed the “exclusive commercialization rights” to the three most lucrative areas of embryonic stem cell research if treatments are ever found – spinal cord injury, heart disease, and diabetes.

Geron’s juggernaut culminated last year with the FDA’s first approval of embryonic stem cell treatment on human spinal cord injured patients, “triggering a wave of ebullience from scientists, investors and patient advocates,” according to the California Stem Cell Report.

...In all, Geron invested 15 years and a whopping $150 million into embryonic stem cell research.

Only to abruptly dump it? What a difference a year makes. The value of Geron’s stock in the past year has fallen 70%, and since last week’s announcement it has only sunk lower. It is laying off 38% of its workers.

Why are they getting out?

But I am not alone in sensing something more is afoot. One speculation, according to Science Magazine:

The development of induced pluripotent stem (iPS) cells, which are adult cells genetically reprogrammed to resemble embryonic ones, means that Geron’s exclusive licenses may be worth less.

Or worthless, hopefully – obsolete. iPS cells are skin cells thought to have the same ability as embryonic stem cells to grow a variety of ways 1) without the controversy; and 2) without the potential for rejection, since iPS cells come from a patient’s own body and not someone else’s, such as cells from embryos.

Another possibility, quoting ABC News:

“This company would not walk away from this trial in the absence of an unexpected complication or safety concern, if there was any evidence that it was working,” said Dr. Daniel Salomon, associate professor in the department of molecular and experimental medicine at the Scripps Research Institute in San Diego.

I spoke with Dr. David Prentice (pictured right) of Family Research Council today. Dr. Prentice is an expert in the field of stem cell research.

Dr. Prentice also speculates something went wrong with the spinal cord trials, which will eventually come to light if true.

“Note the phrase that always shows up,” said Dr. Prentice, “that there are no ‘serious‘ adverse events,” a red flag he thinks.

This is true. Quoting the Associated Press: “So far, the treatment… has been tolerated well without any serious side effects, the company said.”

...Dr. Prentice suspects Geron’s embryonic stem cell department has become a “hot potato” it will now find difficult to dump. The very fact it is halting embryonic stem cell research for economic reasons makes it economically unappealing to buyers.

What impact will this have on embryonic stem cell research in general?

Some say Geron’s decision may have dealt a death knell to embryonic stem cell research altogether, “wonder[ing] whether the field of embryonic stem cell research has been abandoned in the U.S. completely,” according to ABC.

That may be true of investors, but there’s always government funding,
i.e., money belonging to you and I.

Looks who's really manipulating science for political purposes -- Obama's embryonic stem cell policy.

President Obama announced he would reverse President Bush's policy on federally funded embryonic stem cell research. He'll now allow the federal government to fund programs which destroy embryos for research purposes.

He claims he's returning science to it's rightful place in the arena of embryonic stem cell research according to an AP news story.

"Our government has forced what I believe is a false choice between sound science and moral values," Obama declared as he signed documents changing U.S. science policy and removing what some researchers have said were shackles on their work.

"It is about ensuring that scientific data is never distorted or concealed to serve a political agenda - and that we make scientific decisions based on facts, not ideology," Obama said.

In fact, the exact opposite is happening. Obama is using ideology to distort science and ethics. Science demonstrates that human life begins at conception and despite this fact President Obama says it's OK to perform medical experiments on innocent human life.

Science is also showing ways to use adult stem cell research to provide over 70 treatments for various diseases and conditions. And it's created a way to derive embryonic-like stem cells from adult stem cells. Both of these approaches avoid the ethical issues arising from the performing of experiments on innocent human beings. Of course, this is all ignored in the drive to use innocent human life as a means.

Of course, the extrapolation of this ideology was expressed in the human experiments performed by the Nazis during World War II. Of course, they would have argued they were merely trying to make medical advances.

Ideas do have consequences and dangerously so when ideology trumps ethics.

Embryonic stem cell breakthrough to reshape stem cell debate

A new discovery on the stem cell scene looks like it could well reshape the debate over the use of embryonic stem cell tissue. The new method allows human adult skin cells to be changed to act like embryonic stem cells. This allows people to sidestep the issue of destroying human embryos to harvest their cells.

Researchers in Wisconsin and Japan have turned ordinary human skin cells into what are effectively embryonic stem cells without using embryos or women's eggs -- the two hitherto essential ingredients that have embroiled the medically promising field in a long political and ethical debate.

By activating a few dormant genes, the researchers were able to coax the cells back to a point in embryonic development before they had committed to becoming a particular type of tissue. The reprogrammed cells were able to grow into all the body's main tissue types, including muscle, gut, cartilage, neurons and heart cells.

The discovery provides a clear road map for creating genetically matched replacement cells that could be used to treat patients for a variety of diseases -- the personalized biological repair kits that are the ultimate goal of regenerative medicine.

While this may well dramatically change the overall debate, those ideologically driven to support the destruction of human embryos to harvest their cells will not be persuaded. In another story you can hear ideology driving a proponent of embryonic stem cell legislation.

"I don't think this changes the debate," said Rep. Diana DeGette (D-Colo.), a key participant in the House debate. "We still need to encourage all types of research, and we need to put ethical oversight in place."

For those not ideologically driven I think it will change the debate.